Gelonghui, Feb. 26 | Aodong, Jilin (000623.SZ) said on the investor interactive platform that the company is a pharmaceutical manufacturer, mainly engaged in R&D, manufacturing and sales of traditional Chinese medicines and chemicals. Currently, the company's business scope covers proprietary Chinese medicines, traditional Chinese medicine formula granules, Chinese medicine tablets, chemicals, etc., while actively laying out health food, food, breeding, planting and other fields, gradually forming a “pharmaceutical+finance+big health” multi-wheel drive development model. The company has no CXO and CRO related businesses.
吉林敖东(000623.SZ)：未布局CXO和CRO相关业务
Aodong, Jilin (000623.SZ): CXO and CRO related businesses have not been deployed
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.